Theralase Technologies Inc (TLTFF)

[123414]

TLTFF GBM RG2 cells were pre-treated in vitro with Theralase® CLT. Six hours post treatment, these same cancer cells were irradiated with X-rays. Post-treatment analysis demonstrated that GBM RG2 cancer cells pre-treated with Theralase® CLT then subjected to X-ray had a 20% greater cell kill versus cancer cells treated with X-ray alone, strongly suggesting that the reversal of the Warburg Effect is essential to overcoming resistance to X-rays and improving overall cancer cell kill.
http://theralase.com/pressrelease/theralase-discovers-theralaser-cold-laser-therapy-enhances-cancer-destruction-for-standard-cancer-treatments/

This is from November 30, 2017.

They have had this laser approved for use for a while, There are a lot of things these folks are working on. Cutting edge technology for an excellent purpose. People get focused on the NMIBC study, but they have several irons in the fire.